JIC
TTPH

Joel Isaacson & Co’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Joel Isaacson & Co’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-250
Closed -$20K – 582
2016
Q4 		$20K Hold
250
– – ﹤0.01% 431
2016
Q3 		$19K Hold
250
– – ﹤0.01% 471
2016
Q2 		$22K Hold
250
– – ﹤0.01% 454
2016
Q1 		$23K Hold
250
– – 0.01% 468
2015
Q4 		$50K Buy
+250
New +$49.9K 0.01% 326

Other funds holding TTPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Joel Isaacson & Co's TTPH Position: Q1 2017 in Review

Joel Isaacson & Co sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q1 2017, closing a stake of 250 shares — an estimated $20K sold.

Joel Isaacson & Co first reported a position in TTPH in Q4 2015 and held it in 5 quarters. The position peaked at $50K in Q4 2015. 89 funds tracked by Wall St. Rank hold TTPH as of Q1 2017.

  • Joel Isaacson & Co reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • Joel Isaacson & Co sold 250 Tetraphase Pharmaceuticals, Inc. shares in Q1 2017, an estimated $20K.
  • Joel Isaacson & Co first reported a position in Tetraphase Pharmaceuticals, Inc. in Q4 2015 and held it in 5 quarters.
  • Joel Isaacson & Co's Tetraphase Pharmaceuticals, Inc. position peaked at $50K in Q4 2015.
  • 89 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q1 2017.

Based on Joel Isaacson & Co's 13F filing for Q1 2017, filed 5 May 2017.